421 related articles for article (PubMed ID: 26613512)
1. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
[TBL] [Abstract][Full Text] [Related]
4. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway.
Yu JJ; Zhang Y; Wang Y; Wen ZY; Liu XH; Qin J; Yang JL
Psychopharmacology (Berl); 2013 Jan; 225(2):361-72. PubMed ID: 22875481
[TBL] [Abstract][Full Text] [Related]
7. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
[TBL] [Abstract][Full Text] [Related]
8. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
[TBL] [Abstract][Full Text] [Related]
9. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
[TBL] [Abstract][Full Text] [Related]
10. Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors.
Petrara MR; Serraino D; Di Bella C; Neri F; Del Bianco P; Brutti M; Carmona F; Ballin G; Zanini S; Rigotti P; Furian L; De Rossi A
Cancer Lett; 2020 Jan; 469():323-331. PubMed ID: 31693921
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
12. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
14. Burkitt lymphoma after transplant: an aggressive lymphoproliferative disease.
Akar Özkan E; Özdemir BH; Akdur A; Deniz EE; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():136-8. PubMed ID: 24635811
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Thoms KM; Kuschal C; Oetjen E; Mori T; Kobayashi N; Laspe P; Boeckmann L; Schön MP; Emmert S
Exp Dermatol; 2011 Mar; 20(3):232-6. PubMed ID: 21323745
[TBL] [Abstract][Full Text] [Related]
17. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
18. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
19. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
[TBL] [Abstract][Full Text] [Related]
20. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
Navarro-Villarán E; Tinoco J; Jiménez G; Pereira S; Wang J; Aliseda S; Rodríguez-Hernández MA; González R; Marín-Gómez LM; Gómez-Bravo MA; Padillo FJ; Álamo-Martínez JM; Muntané J
PLoS One; 2016; 11(8):e0160979. PubMed ID: 27518575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
